Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection.

Stinton LM, Myers RP, Coffin CS, Fritzler MJ.

BMC Gastroenterol. 2013 Mar 19;13:50. doi: 10.1186/1471-230X-13-50.

2.

Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-α/ribavirin therapy.

Keppeke GD, Calise SJ, Chan EK, Andrade LE.

World J Gastroenterol. 2016 Feb 14;22(6):1966-74. doi: 10.3748/wjg.v22.i6.1966. Review.

3.

Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients.

Novembrino C, Aghemo A, Ferraris Fusarini C, Maiavacca R, Matinato C, Lunghi G, Torresani E, Ronchi M, Garlaschi MC, Ramondetta M, Colombo M.

J Viral Hepat. 2014 Dec;21(12):944-9. doi: 10.1111/jvh.12281. Epub 2014 Jul 14.

PMID:
25040504
4.

Development of a recombinant cell-based indirect immunofluorescence assay (RC-IFA) for the determination of autoantibodies against "rings and rods"-associated inosine-5'-monophosphate dehydrogenase 2 in viral hepatitis C.

Probst C, Radzimski C, Blöcker IM, Teegen B, Bogdanos DP, Stöcker W, Komorowski L.

Clin Chim Acta. 2013 Mar 15;418:91-6. doi: 10.1016/j.cca.2013.01.003. Epub 2013 Jan 16.

PMID:
23333419
5.

Differential reactivity to IMPDH2 by anti-rods/rings autoantibodies and unresponsiveness to pegylated interferon-alpha/ribavirin therapy in US and Italian HCV patients.

Carcamo WC, Ceribelli A, Calise SJ, Krueger C, Liu C, Daves M, Villalta D, Bizzaro N, Satoh M, Chan EK.

J Clin Immunol. 2013 Feb;33(2):420-6. doi: 10.1007/s10875-012-9827-4. Epub 2012 Oct 26.

PMID:
23100146
6.

Longitudinal study of a human drug-induced model of autoantibody to cytoplasmic rods/rings following HCV therapy with ribavirin and interferon-α.

Keppeke GD, Nunes E, Ferraz ML, Silva EA, Granato C, Chan EK, Andrade LE.

PLoS One. 2012;7(9):e45392. doi: 10.1371/journal.pone.0045392. Epub 2012 Sep 24.

7.

Autoantibodies against inosine-5'-monophosphate dehydrogenase 2--characteristics and prevalence in patients with HCV-infection.

Seelig HP, Appelhans H, Bauer O, Blüthner M, Hartung K, Schranz P, Schultze D, Seelig CA, Volkmann M.

Clin Lab. 2011;57(9-10):753-65.

PMID:
22029192
8.

Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C.

Covini G, Carcamo WC, Bredi E, von Mühlen CA, Colombo M, Chan EK.

Antivir Ther. 2012;17(5):805-11. doi: 10.3851/IMP1993. Epub 2011 Dec 1.

PMID:
22293655
9.

Temporal evolution of human autoantibody response to cytoplasmic rods and rings structure during anti-HCV therapy with ribavirin and interferon-α.

Keppeke GD, Satoh M, Ferraz ML, Chan EK, Andrade LE.

Immunol Res. 2014 Oct;60(1):38-49. doi: 10.1007/s12026-014-8515-2.

PMID:
24845459
10.

Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C.

Muratori P, Muratori L, Guidi M, Granito A, Susca M, Lenzi M, Bianchi FB.

Clin Infect Dis. 2005 Feb 15;40(4):501-7. Epub 2005 Jan 21.

PMID:
15712070
11.
12.

Chronic hepatitis C virus infection in renal transplant: treatment and outcome.

Sharma RK, Bansal SB, Gupta A, Gulati S, Kumar A, Prasad N.

Clin Transplant. 2006 Nov-Dec;20(6):677-83.

PMID:
17100715
13.

The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C.

Wasmuth HE, Stolte C, Geier A, Dietrich CG, Gartung C, Lorenzen J, Matern S, Lammert F.

BMC Infect Dis. 2004 Feb 13;4:4.

14.

Interferon therapy in LKM-1 positive patients with chronic hepatitis C: follow-up by a quantitative radioligand assay for CYP2D6 antibody detection.

Duclos-Vallée JC, Nishioka M, Hosomi N, Arima K, Leclercq A, Bach JF, Yamamoto AM.

J Hepatol. 1998 Jun;28(6):965-70.

PMID:
9672171
15.

Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection.

Aghemo A, Rumi MG, Soffredini R, D'Ambrosio R, Ronchi G, Del Ninno E, Gallus S, Colombo M.

Antivir Ther. 2006;11(6):797-802.

PMID:
17310824
16.

Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.

Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR.

Hepatology. 2001 Mar;33(3):704-7.

PMID:
11230751
17.

[Serum autoantibodies of patients with chronic hepatitis C and the significance thereof in infection of hepatitis C virus].

Wu CH, Xu XY, Tian GS, Yu YY.

Zhonghua Yi Xue Za Zhi. 2006 Feb 14;86(6):390-3. Chinese.

PMID:
16677548
18.
19.

Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies.

Soriano V, Maida I, Núñez M, García-Samaniego J, Barreiro P, Martín-Carbonero L, González-Lahoz J.

Antivir Ther. 2004 Dec;9(6):987-92.

PMID:
15651757
20.

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.

Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

Clin Drug Investig. 2008;28(1):9-16. Erratum in: Clin Drug Investig. 2008;28(4):210.

PMID:
18081356

Supplemental Content

Support Center